Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
Over the past decade, outbreaks of H1N1 influenza, Sars-Cov, Ebola, and MERS have sparked ongoing conversations about strategic approaches and responses to pandemics and epidemics. Now with the spread of SARS-CoV-2 intensifying, scientists, together with pharmaceutical companies, are reinventing the approach of how to bring these life-saving drugs to market faster without impacting product quality, safety, or efficacy.
Listen to this on-demand webinar to hear industry expert, Vincenza Pironti, discuss: